1[1]Chao J, Chao L. Experimental kallikrein gene therapy in hypertension, cardiovascular and renal disease. Pharmacol Res. 1997; 35:517-522
2[2]Lin KF, Chao J, Chao L. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension. 1997; 30:307-313
3[3]Chao J, Jin L, Lin KF et al. Adrenomedullin gene delivery reduces blood pressure in spontaneously hypertensive rats. Hypertens Res. 1997;20:2692-2677
4[4]Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum Gene Ther. 1998;9:1429-1438
5[5]Dobrzynski E, Yoshida H, Chao J et al. Adenovirusmediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxydcorticosterone-salt rats.Immunopharmacology. 1999; 44:57-65
6[6]Emanueli C, Salis MB, Stacca T et al. Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene transfer. Hypertension. 2001 Jul;38 (1) :136-41
7[7]Zhao C, Wang P,Xiao X et al. Gene Therapy With Human Tissue Kallikrein Reduces Hypertension and Hyperinsulinemia in Fructode-Indeced Hypertensive Rats. Hypertension. 2003 Oct 20 [Epub ahead of print] .
8[8]Zhang YC, Bui JD, Shen L et al. Antisense inhibition of β1-adrenergic receptor mRNA in a single dose produce a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats. Circulation. 2000; 101:682-688
9[9]Kumai T, Tateishi T, Tanaka M. Tyrosine hydroxylase antisense gene therapy causes hypotensive effects in the spontaneously hypertensive rats. J Hypertens. 2001 Oct; 19 (10) :1769-73
10[10]Kishioka H, Fukuda N, Wen-Yang H et al. Effects of PDGF A-chain antisense oligodeoxynucleotides on growth of cardiovascular organs in stroke-prone spontaneously hypertensive rats. Am J Hypertens. 2001 May; 14 (5 Pt 1) :439-45
